Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Journey Medical Corporation DERM NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
48/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$11.75
+123.4%

Journey Medical Corporation (DERM) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $5.26. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is DERM = $12 (+123.4% upside).

Valuation: DERM trades at a trailing Price-to-Earnings (P/E) of -10.8 (S&P 500 average ~25).

Financials: revenue is $62M, -3.8%/yr average growth. Net income is $11M (loss), growing at -57.2%/yr. Net profit margin is -18.5% (negative). Gross margin is 59.3% (+1.1 pp trend).

Balance sheet: total debt is $119,000 against $32M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 1.79 (strong liquidity). Debt-to-assets is 0.1%. Total assets: $95M.

Analyst outlook: 3 / 3 analysts rate DERM as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

$11.75
▲ 123.38% Upside
Average Price Target
Based on 3 Wall Street analysts offering 12-month price targets for Journey Medical Corporation, the average price target is $11.75, with a high forecast of $13.00, and a low forecast of $10.50.
Highest Price Target
$13.00
Average Price Target
$11.75
Lowest Price Target
$10.50

DERM SharesGrow Score Overview

56/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — DERM

✓
VALUE Pass
100/100
DERM trades at a trailing Price-to-Earnings (P/E) of -10.8 (S&P 500 average ~25). Forward PEG -0.01 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.32. Analyst consensus target is $12, implying +128.1% from the current price $5. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
DERM: -3.8%/yr revenue is, -57.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet DERM: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 1.79 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
DERM: Gross margin is 59.3% (+1.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 3 / 3 analysts rate DERM as buy (100%). Analyst consensus target is $12 (+128.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
DERM: Net profit margin is -18.5%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range4.31-9.555
Volume118.39K
Avg Volume (30D)205.28K
Market Cap$128.86M
Beta (1Y)1.04
Share Statistics
EPS (TTM)-0.47
Shares Outstanding$24.5M
IPO Date2021-11-12
Employees41
CEOClaude Maraoui
Financial Highlights & Ratios
Revenue (TTM)$61.86M
Gross Profit$36.68M
EBITDA$-3.83M
Net Income$-11.43M
Operating Income$-8.17M
Total Cash$24.09M
Total Debt$119K
Net Debt$-23.97M
Total Assets$94.59M
Price / Earnings (P/E)-11.2
Price / Sales (P/S)2.08
Analyst Forecast
1Y Price Target$11.75
Target High$13.00
Target Low$10.50
Upside+123.4%
Rating ConsensusBuy
Analysts Covering3
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS48115J1097

Price Chart

Track all markets on TradingView
DERM
Journey Medical Corporation ↗  ·  NASDAQ Capital Marke
Healthcare • Drug Manufacturers - Specialty & Generic
4.31 52WK RANGE 9.56

People Also View

AVDL
AVDL
Avadel Pharmaceuticals plc
$21.64
+0.00%
 CURLF
CURLF
Curaleaf Holdings, Inc.
$2.40
+0.04%
 TCNNF
TCNNF
Trulieve Cannabis Corp.
$6.47
+2.73%
 AQST
AQST
Aquestive Therapeutics, Inc.
$4.15
-0.95%
 ORGO
ORGO
Organogenesis Holdings Inc.
$2.51
+5.46%
 CRLBF
CRLBF
Cresco Labs Inc.
$0.92
+0.48%
 ALIM
ALIM
Alimera Sciences, Inc.
$5.54
-0.18%
 ACB
ACB
Aurora Cannabis Inc.
$3.53
+1.44%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message